ABBV, is it a buy right now?

☝️ Losing patent protection for a top-selling blockbuster drug is a big setback for any pharmaceutical company, but this can also give us great opportunities. They have done a great strategic-movement by acquiring Allergan.

It's down 18% from last July 17 high, earnings are close. I believe, yes, it's a good moment to START doing COST-AVERAGE.

The price is almost getting closer to the 50% Fibonacci (from last Mar 20). I'm protecting an optimistic retracement to 127% (at $108.58) Fibonacci (drawing from today), very close to the analyst's current average price target at $109.21. A more conservative take profit would be at $95.

- P/E GAAP (TTM) of 18.63, sector media of 35.57 👍
- Forward P/E of 6.94 👍
- PEG GAAP (TTM) of 0.29, sector media of 0.88 👍
- EV / EBITDA (TTM) of 13.76 in a sector media of 19.29 👍
- Debt / Eq of 5.4 😐
- Dividend yield of 5.60% 😍

Nothing else to say, it's a great company, with great dividends. I'm in! 👌

This isn't trading advice. I've no idea what I'm talking about 😉.

Trade with caution! 🚨

Have a good day! 🤟